Andrew Cheng, President en CEO van Akero Therapeutics, Inc. (NASDAQ:AKRO), een biotechnologiebedrijf dat volgens InvestingPro -analyse momenteel tekenen van onderwaardering vertoont, heeft op 11 augus ...

Directeur Jane Henderson van Akero Therapeutics, Inc. (NASDAQ: AKRO ), een bedrijf met een marktkapitalisatie van $ 3,84 mld., heeft op 12 augustus 2025 3.000 gewone aandelen verkocht tegen een prijs ...

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3 study titled ‘A Phase ...

Akero Therapeutics, Inc. (NASDAQ: AKRO) President and CEO Andrew Cheng recently sold shares in the company, yielding a total of $178,728. The transaction, which took place on June 11, involved the ...

Akero Therapeutics shares gained 117% in early trading on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse scarring of the organ without worsening ...

The positions in the table below reflect the Akero Therapeutics's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...

Akero Therapeutics has been a focus of several analyst firms. Canaccord Genuity maintained a Buy rating on the company's stock, noting the potential of the drug candidate, Efruxifermin.

In a recent SEC filing, Rolph Timothy, Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ: AKRO), disclosed the sale of company shares valued at approximately $1.74 million. The transactions ...

Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ: AKRO), recently executed a notable share sale, as per the latest SEC filing. The timing is particularly interesting as ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) is up 71.75% year-to-date. Overall AKRO ranks 4th on our list of the biotech stocks that are skyrocketing so far in 2025.